In this Issue:
As the UN convenes to discuss the Ebola epidemic in West Africa, Bloomberg Businessweek reveals that the United States lost nearly two years in developing and getting approval for ZMapp, an experimental Ebola antibody cocktail that is to date the world’s best hope against a virus with an over 50 percent death rate. With the pandemic escalating, why hadn’t the promising treatment gone through human clinical trials sooner than September 2, 2014, and why are there so few doses on hand? Take a look for yourself.
Get every issue of Bloomberg Businessweek Magazine and unlimited access to over 140 top magazines in one app, including back issues. Try Free at NextIssue.com
About Bloomberg Businessweek Magazine:
The Bloomberg Businessweek Magazine provides you with an in-depth analysis on global business, finance and economy. Latest options, informaton and opinions about all the happenings in the ever-changing world of business.